The panel will focus on developing industry perspectives on partnering with academia and other industrial partners. Specifically, the panel will be comprised of business development and marketing experts from the medical device and pharmaceutical industry that have experience in organizing partnering collaborations, licensing deals, and acquisition deals with industry and/or academic institutions. This discussion will also touch on funding such collaborative initiatives as well as how to protect intellectual property that may arise in such collaborations. The panel discussion will last 45 minutes.
Rafael V. Andino
Vice President, Product Development
Clearside Biomedical, Inc.
Rafael V. Andino is a biomedical engineer and businessman having 25 years of experience in the pharmaceutical and medical device industry in both public and private companies. He has served in product development, research and development and general management roles and has led multidisciplinary and multinational teams to launch successful products in many fields of medicine including ophthalmology, urology, endourology, gynecology, wound care, cardiovascular and general surgery.
Mr. Andino is currently Vice President of Product Development at Clearside Biomedical in Alpharetta, Georgia. Clearside Biomedical is an ophthalmic pharmaceutical company developing and commercializing targeted therapeutics for the treatment of sight threatening diseases using a proprietary disruptive drug delivery technology. Before joining the Clearside management team, he was Director of R&D at Bard Medical, a division of C.R. Bard, Inc., a top 20 global medical device manufacturer with sales in excess of $2.5 billion (NYSE: BCR). Prior to Bard, he founded and led Biofisica, Inc. which developed breakthrough technology to expedite wound healing and regeneration of connective tissue in humans. In 2007, Biofisica launched the first wound care product of its kind, POSIFECT®, in the United Kingdom. Prior to founding Biofisica, Mr. Andino was an R&D Director and senior project manager for CIBA VISION® (a Novartis company), a leading global contact lens and lens care company. He has also worked for the global technology companies E.I. DuPont de Nemours, General Electric and IBM.
Mr. Andino is also an Adjunct Professor in the Wallace H. Coulter Department of Biomedical Engineering within the Georgia Institute of Technology and Emory University School of Medicine in Atlanta, Georgia. Additionally, he is a Lieutenant Colonel in the United States Air Force Reserve, serving as Chief of Medical Support and the Administrator for the 413th Aeromedical Staging Squadron at Robins Air Force Base, Georgia.
Mr. Andino obtained a Bachelor’s degree in Mechanical Engineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and an MBA from Mercer University in Atlanta, GA.
Brian K. Adams, PhD, MBA
Vice President, Business Development
Arbor Pharmaceuticals, LLC
Dr. Adams has a career of over 15 years in the life sciences in both academia and industry. Prior to joining Arbor, he served as Head of Business Development at Cornerstone Therapeutics and Senior Director of Business Development at Shionogi Pharma (formerly Sciele Pharma). Brian originally started with Shionogi as the Intellectual Property Manager and was responsible for handling the company’s patents and trademarks. Before working for Shionogi, he served as a patent agent and scientific advisor at Pabst Patent Group LLP and Holland & Knight, LLP in the areas of biotechnology and chemistry. He has been very active in the Southeast life sciences community and is a member of the SE BIO Board of Directors. Brian has earned a B.S. in Biology from Wake Forest University, a PhD in Molecular and Systems Pharmacology from Emory University, and an MBA from the University of Georgia.
David Stern, ME
St. Jude Medical
David R. Stern was the first employee of CardioMEMS, Inc., an Atlanta based medical device company that successfully developed the recently approved CardioMEMS HF System, a wireless sensing and communication technology designed to improve the management of heart failure. In June, CardioMEMS was acquired by St. Jude Medical, where Mr. Stern is now the Vice President of R&D and the Atlanta Site Leader. Prior to joining CardioMEMS, Mr. Stern was Vice President and Business Unit Manager of the Peripheral Technologies Division of C.R. Bard.
Mr. Stern is a former president and current board member of the Southeast Medical Device Association and is the Co-Chairman of Georgia Bio’s Medical Device Network. He also currently serves on the Georgia Tech Biomedical Engineering Advisory Board.
Mr. Stern has a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, a M.E. in Biomedical Engineering from Worcester Polytechnic Institute and is the holder of 11 patents.
Manuel Kingsley, MBA
The Questus Group
Manuel Kingsley, Managing Director for The Questus Group is often called the Growth Expert. He has helped clients achieve dramatic growth by providing deep understanding of customers and markets, developing pragmatic strategies and showing clients how to align their operations to achieve both top line growth as well as profit. He marries rigorous analysis with experience that leads to valuable insights defying conventional wisdom.
Manuel has helped clients lay the groundwork for new growth opportunities, revolutionize operating models, and ignite business expansion. He has an MBA from University of North Carolina at Chapel Hill, an MS in Operations and a BS in Industrial Engineering. After earning his MBA, Manuel worked for McKinsey & Company, advising clients in telecom, retail, industrial goods and B2B services on growth and corporate strategy. He served for over fifteen years in multiple roles across the Med Tech, Life Sciences and Diagnostics industries.
Glenn Noronha, PhD
Executive Vice President, R&D
Dr. Noronha has served as our Executive Vice President, Research and Development since August 2013. From August 2012 to May 2013, he served as Vice President, Research and Development at Sucampo Pharma Americas, LLC, a pharmaceutical company. From July 2011 to July 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development. From 2008 to 2011, Dr. Noronha was Global Project Head for Retinal Development at Alcon Laboratories, Inc., a Novartis company. From 2002 to 2008, Dr. Noronha held several positions at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs. Previously, from 2000 to 2002, he was a research scientist and project leader for Medtronic MiniMed, Inc. Dr. Noronha received his Ph.D. degree from Loyola University of Chicago and was a post-doctoral fellow at the University of California at Irvine.